5 terminated, 4 completed, 2 active not recruiting, 2 recruiting. 17 Phase 2, 4 Phase 1.
Follow Pleural Mesothelioma: new trials by email Literature Review of Pleural Mesothelioma trials Research Report on Pleural Mesothelioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma [68Ga]Ga-FAPI-46 PET/CT - Pleural Mesothelioma, Pleural Diseases | Phase 2 | Recruiting | Aalborg University Hospital | 70 | 2025-01-29 | 2025-07-03 |
| Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) Carboplatin/Cisplatin - Pemetrexed - Pembrolizumab - Pleural Mesothelioma | Phase 2 | Active not recruiting | Istituto Oncologico Veneto IRCCS | 41 | 2024-11-06 | 2026-01-13 |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Alintegimod, Ipilimumab, Nivolumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | 7 Hills Pharma, LLC | 126 | 2024-08-23 | 2026-04-13 |
| Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma Cadonilimab Combined with chemotherapy - Pleural Mesothelioma | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 59 | 2024-06-20 | 2024-05-16 |
| Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin - Pleural Mesothelioma | Phase 2 | Unknown | Sun Yat-sen University | 38 | 2023-11-01 | 2024-02-21 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers XmAb20717 - Microsatellite High Cancers, Peritoneal Mesothelioma | Phase 2 | Suspended | M.D. Anderson Cancer Center | 140 | 2022-08-05 | 2026-10-13 |
| A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) THOR-707, Pembrolizumab - Pleural Mesothelioma, Non-small Cell Lung Cancer | Phase 2 | Terminated | Sanofi | 106 | 2021-09-23 | 2025-10-02 |
| A Beta-only IL-2 ImmunoTherapY Study MDNA11, Pembrolizumab (KEYTRUDA®) - Advanced Solid Tumor, Unresectable Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | Medicenna Therapeutics, Inc. | 160 | 2021-08-27 | 2026-10-30 |
| Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma Durvalumab - Mesothelioma, Pleural Mesothelioma | Phase 2 | Completed | PrECOG, LLC. | 55 | 2017-06-13 | 2023-07-05 |
| A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1) tremelimumab plus MEDI4736 - Pleural Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Unknown | Italian Network for Tumor Biotherapy Foundation | 40 | 2015-10-01 | 2015-10-27 |
| TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients Cyclophosphamide, Fludarabine, Autologous tumor infiltrating lymphocytes (TILs) - Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 9 | 2015-05-15 | 2023-01-10 |
| Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy IMC-A12 - Pleural Mesothelioma, Peritoneal Mesothelioma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2010-06-02 | 2018-04-10 |
| Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma Pemetrexed, Cisplatin - Mesothelioma, Pleural Mesothelioma | Phase 2 | Terminated | University Health Network, Toronto | 6 | 2009-01-01 | 2017-05-04 |
| Trimodal Lung-Sparing Treatment of Pleural Mesothelioma Doxorubicin, Cisplatin, Pemetrexed - Pleural Mesothelioma | Phase 2 | Terminated | Columbia University | 9 | 2008-02-01 | 2020-08-25 |
| Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Cisplatin, Sodium Thiosulfate, ALIMTA - Pleural Mesothelioma, Malignant Pleural Mesothelioma | Phase 2 | Terminated | Dana-Farber Cancer Institute | 16 | 2004-04-01 | 2016-09-09 |
| Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate Cisplatin, Sodium Thiosulfate - Pleural Mesothelioma, Malignant Pleural Mesothelioma | Phase 2 | Completed | Dana-Farber Cancer Institute | 85 | 2004-01-01 | 2014-03-27 |
Mesothelioma, Malignant (17) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Renal Cell (3) · Melanoma (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Colorectal Neoplasms (2) · Endometrial Neoplasms (2) · Esophageal Neoplasms (2) · Mesothelioma (2) · Skin Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Stomach Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Turcot syndrome (2)
Adenoma (17) · Lung Diseases (17) · Lung Neoplasms (17) · Neoplasms by Histologic Type (17) · Neoplasms by Site (17) · Neoplasms, Glandular and Epithelial (17) · Neoplasms, Mesothelial (17) · Pleural Neoplasms (17) · Respiratory Tract Diseases (17) · Respiratory Tract Neoplasms (17) · Thoracic Neoplasms (17) · Mesothelioma (15) · Neoplasms (14) · Adenocarcinoma (4) · Bronchial Neoplasms (4)
Cisplatin (4) · pembrolizumab (4) · Pemetrexed (3) · Interleukin-2 (2) · durvalumab (2) · sodium thiosulfate (2) · Carboplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Drug Therapy (1) · Drugs, Generic (1) · ING2 protein, human (1) · Ipilimumab (1) · Leucovorin (1)
Dana-Farber Cancer Institute (2) · University Health Network, Toronto (2) · 7 Hills Pharma, LLC (1) · Aalborg University Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Columbia University (1) · Istituto Oncologico Veneto IRCCS (1) · Italian Network for Tumor Biotherapy Foundation (1) · M.D. Anderson Cancer Center (1) · Medicenna Therapeutics, Inc. (1) · National Cancer Institute (NCI) (1) · NuCana plc (1) · PrECOG, LLC. (1) · Sanofi (1) · Sun Yat-sen University (1)
United States (9) · Canada (3) · Italy (3) · Australia (2) · South Korea (2) · Spain (2) · Argentina (1) · Chile (1) · China (1) · Denmark (1) · France (1) · Ireland (1) · Japan (1) · Poland (1) · Portugal (1)
David J. Sugarbaker, MD (2) · Arash Yavari, MBBS (1) · Arvind Nageshwara Dasaru, MD (1) · Giulia Pasello, MD (1) · Helle Zacho, MD, DMSc (1) · Lionel Lewis, MA, MB.Bch, MD (1) · Luana Calabro', MD, PhD (1) · Marcus Butler, M.D. (1) · Nina Merchant (1) · Patrick Forde, MD (1) · Raffit Hassan, M.D. (1) · Robert N Taub, MD, PhD (1) · Ron Feld, MD (1)
PMID 29773326, PMID 33844995, PMID 34499875, PMID 34750557
2023 (1)